Pure Biologics Spólka Akcyjna Asset Resilience Ratio
Pure Biologics Spólka Akcyjna asset resilience ratio. Pure Biologics Spólka Akcyjna (PUR) has an Asset Resilience Ratio of 6.13% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PUR cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Pure Biologics Spólka Akcyjna (2021–2022)
Asset resilience ratio of Pure Biologics Spólka Akcyjna from 2021 to 2022. This chart shows how Pure Biologics Spólka Akcyjna's Asset Resilience Ratio has changed over time. Read how much debt does Pure Biologics Spólka Akcyjna carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Pure Biologics Spólka Akcyjna's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Pure Biologics Spólka Akcyjna.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 0% |
| Short-term Investments | zł3.99 Million | 6.13% |
| Total Liquid Assets | zł3.99 Million | 6.13% |
Asset Resilience Insights
- Limited Liquidity: Pure Biologics Spólka Akcyjna maintains only 6.13% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Pure Biologics Spólka Akcyjna Industry Peers by Asset Resilience Ratio
Compare Pure Biologics Spólka Akcyjna's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Samsung Biologics Co Ltd
KO:207940 |
Biotechnology | 15.21% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Asymchem Laboratories Tian Jin Co Ltd
SHE:002821 |
Biotechnology | 5.07% |
|
Immunovant Inc
NASDAQ:IMVT |
Biotechnology | 98.50% |
|
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578 |
Biotechnology | 21.11% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Amicus Therapeutics Inc
NASDAQ:FOLD |
Biotechnology | 8.37% |
Pure Biologics Spólka Akcyjna Asset Resilience Ratio by Year (2021–2022)
Pure Biologics Spólka Akcyjna asset resilience ratio by year from 2021 to 2022. The table below shows the annual Asset Resilience Ratio data for Pure Biologics Spólka Akcyjna.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | 14.90% | zł4.92 Million ≈ $1.35 Million |
zł33.01 Million ≈ $9.08 Million |
-41.79pp |
| 2021-12-31 | 56.69% | zł26.75 Million ≈ $7.36 Million |
zł47.19 Million ≈ $12.99 Million |
-- |
About Pure Biologics Spólka Akcyjna
Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFß1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the aVß8 integrin. The company was founded… Read more